GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Beckman Coulter, Inc. (BEC) [hlAlert]

Rating:
Outperform
BEC
up 21.09 %

Beckman Coulter, Inc. (BEC) rated Outperform by Leerink Swann

Posted on: Wednesday,  Apr 30, 2008  12:25 PM ET by Leerink Swann

Leerink Swann rated Outperform Beckman Coulter, Inc. (NYSE: BEC) on 04/30/2008, when the stock price was $68.93.
Since then, Beckman Coulter, Inc. has gained 21.09% as of 06/29/2011's recent price of $83.47.
If you would have followed this Leerink Swann 's recommendation on BEC, you would have gained 21.09% of your investment in 1155 days.

Beckman Coulter, Inc. simplifies and automates laboratory processes used in all phases of the battle against disease. The company designs, manufactures, and markets systems which consist of instruments, chemistries, software, and supplies that meet a variety of laboratory needs. Its products are used in a range of applications, from instruments used for pioneering medical research and drug discovery to diagnostic tools found in hospitals and physicians' offices.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/30/2008 12:25 PM Buy
None
68.93
as of 12/24/2008
1 Week down  -5.32 %
1 Month up  3.57 %
3 Months up  11.20 %
1 YTD down  -25.99 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy